MINNEAPOLIS, MN / ACCESSWIRE / November 24, 2014 / PetVivo Holdings, Inc.
(OTCPINK:PETV) an emerging biomedical device company focused on the licensing
and commercialization of innovative medical devices for pets, or pet
therapeutics is pleased to announce that they have entered into a definitive stock exchange agreement with Gel-Del Technologies,
Inc.

"This merger creates
value for everyone involved," commented PetVivo CEO John Lai, "PetVivo provides
Gel-Del access to capital and product revenues beginning in early 2015, while
PetVivo gains an extensive product and intellectual property portfolio from
Gel-Del."

"I believe we will
create significant value for all stakeholders by combining Gel-Del’s innovative
technology platform and commercial ready product pipeline with PetVivo’s strong
desire to be the veterinary leader in medical device treatments that reduce
pain and bring a better life to animals and their owners." noted Gel-Del’s CEO
Dr. David B. Masters.

Upon approval of PetVivo
and Gel-Del shareholders that includes certain conditions, this merger will
result in an exchange of all outstanding capital stock of Gel-Del with PetVivo.
At the time of closing, which is scheduled to occur on or before March 31, 2015,
Gel-Del will become a wholly owned subsidiary of PetVivo. Gel-Del will continue
with its operations to provide biomaterials and products for human and
veterinary markets.

Gel-Del is a
biomaterial and medical device development and manufacturing company with its
offices and production facilities based in St. Paul, Minnesota, and was founded
in 1999 by its Chief Executive Officer, Dr. David B. Masters. Dr. Masters
developed Gel-Del’s proprietary biomaterials that simulate a body’s cellular
tissue and thus can be readily and effectively utilized to manufacture
implantable therapeutic medical devices.
The chief advantage of Gel-Del biomaterials is their enhanced
biocompatibility with living tissues throughout the body.

PetVivo’s lead product, Kush(TM) Canine, for the treatment of canine osteoarthritis, is scheduled for commercial
launch in Q2 2015, followed shortly thereafter by Kush(TM) Equine for the treatment of lameness in
horses in Q4 of 2015. The particles used to make the Kush devices are part of a
large pipeline of patented animal and human therapeutics developed and
manufactured by Gel-Del Technologies.

About Gel-Del Technologies, Inc:


Gel-Del Technologies (www.gel-del.com) is a biomaterial and
medical device manufacturing company based in St. Paul, Minnesota. The company
successfully completed a pivotal clinical trial using their novel thermoplastic
biomaterial as an injected dermal filler for human facial contour applications
(clinicaltrials.gov NCT00414544).

Gel-Del’s core competencies include the development and
manufacturing of medical devices containing its proprietary biomaterials with
or without pharmaceuticals. Using its patented thermoplastic and/or
compression manufacturing technologies, purified proteins and carbohydrates are
accurately self-assembled and fabricated into cell supporting and tissue compatible biomaterial scaffolds. These
"made from scratch" biological scaffolds have the hydrophilic biomimetic structure of the body's
non-cellular tissue allowing in
vivo biochemical interaction, cellular integration, neovascularization, tissue
repair, and regeneration as a temporary
or permanent implant.

These non-soluble biomaterials are produced using a patented
and reproducible-scalable process that is FDA-validated for human clinical
trial production. The inherent properties of these biomaterials allow
thermoplastic or liquid coating techniques to manufacture implantable
devices of all shapes and sizes, including particles for injection and as drug delivery devices at any
pharmaceutical dose.

About PetVivo, Inc:
PetVivo, Inc. is a wholly owned subsidiary of PetVivo
Holdings, Inc. (OTCPINK:PETV) based in Minneapolis, Minnesota. PetVivo is an
emerging biomedical device company focused on the licensing and
commercialization of innovative medical devices and other therapeutics for
pets.

PetVivo believes that it can leverage the investments in the
human biomaterials and medical device industries to commercialize therapeutics
to pets in a capital and time efficient way. PetVivo's strategy is to
in-license proprietary products from human medical device companies
specifically for use in pets. A key component of this strategy is the
accelerated timeline to revenues for veterinary medical devices, which enter
the market much earlier than the more stringently regulated pharmaceuticals.

Forward-Looking Statements:
The foregoing material may contain forward-looking statements.
We caution that such statements may be subject to uncertainties and that actual
results could differ materially from the forward-looking statements. Readers
accordingly should not place undue reliance on these forward-looking
statements, which do not reflect unknown or unanticipated events or
circumstances occurring after the date of these forward-looking statements.

Contact:
John Lai
Chief Executive Officer
PetVivo Holdings, Inc.
Email: info@petvivo.com
Phone: 612-296-7305


Source: PetVivo, Inc.